Stock Research Monitor: NLNK, OHRP, and ONCS
LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want a free Stock Review on OMER sign up now at www.wallstequities.com/registration. On Monday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.19%; the Dow Jones Industrial Average edged 0.02% higher; and the S&P 500 was up 0.11%. US markets made broad based gains with seven out of nine sectors finishing the day in green. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: NewLink Genetics Corp. (NASDAQ: NLNK), OHR Pharmaceutical Inc. (NASDAQ: OHRP), Omeros Corp. (NASDAQ: OMER), and OncoSec Medical Inc. (NASDAQ: ONCS). All you have to do is sign up today for this free limited time offer by clicking the link below.
Ames, Iowa headquartered NewLink Genetics Corp.'s stock finished Monday's session 0.58% lower at $5.16. A total volume of 381,778 shares was traded. The stock is trading above its 50-day moving average by 0.53%. Furthermore, shares of NewLink Genetics, which focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer, have a Relative Strength Index (RSI) of 51.14. Get the full research report on NLNK for free by clicking below at:
Shares in New York headquartered OHR Pharmaceutical Inc. ended at $0.22, up 5.56% from the last trading session. The stock recorded a trading volume of 221,467 shares. The Company's shares have gained 1.69% in the last month. The stock is trading above its 50-day moving average by 0.27%. Moreover, shares of OHR Pharma, which focuses on the development of novel therapies for the treatment of ophthalmic diseases, have an RSI of 53.61. OHRP's complimentary research coverage is a few simple steps away at:
Seattle, Washington-based Omeros Corp.'s stock ended yesterday's session 0.98% higher at $18.51 with a total trading volume of 680,129 shares. The Company's shares have advanced 14.76% in the past month, 69.66% over the previous three months, and 21.06% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 10.67% and 8.18%, respectively. Additionally, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 47.79. Register for your free research report on OMER at:
On Monday, shares in San Diego, California headquartered OncoSec Medical Inc. recorded a trading volume of 399,136 shares. The stock finished the day 2.01% lower at $1.46. The Company's shares have advanced 35.19% over the last twelve months. The stock is trading below its 50-day moving average by 11.60%. Furthermore, shares of OncoSec Medical, which engages in developing DNA-based intratumoral immunotherapies in the US, have an RSI of 36.41. Wall St. Equities' downloadable research report on ONCS available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities